少数転移性食道がんまたは胃がんの参加者の治療における放射線または手術を伴うまたは伴わない化学療法
少数転移を伴う食道がんまたは胃がん患者に対する早期局所化学放射線療法 +/- 手術と全身療法を比較するランダム化試験
This phase II trial studies how well chemotherapy with or without radiation or surgery works in treating participants with esophageal or gastric cancer that has spread to less than 3 places in the body (oligometastatic). Drugs used in chemotherapy, such as fluorouracil and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Surgery, such as complete surgical resection, may stop the spread of tumor cells by surgically removing organs or tumors. Giving chemotherapy with radiation or surgery may work better than chemotherapy alone in treating participants with oligometastatic esophageal or gastric cancer.
調査の概要
状態
詳細な説明
PRIMARY OBJECTIVES:
I. To evaluate whether esophageal or gastric patients with oligometastatic cancer without disease progression after first line chemotherapy therapy will demonstrate improved overall survival (OS) with early local therapy (concurrent chemotherapy/radiation and surgery).
SECONDARY OBJECTIVES:
I. Assess the relationships between progression-free survival and overall survival between both treatment arms.
II. Report local control, loco-regional control. III. Report time to progression of distant metastases. IV. Report toxicity.
OUTLINE:
Participants receive induction chemotherapy for a minimum of 6 cycles and a maximum of 8 cycles in the absence of disease progression or unacceptable toxicity. Participants are then randomized to 1 of 2 groups.
GROUP I (MAINTENANCE CHEMOTHERAPY): Participants receive fluorouracil and capecitabine per instructions of the treating physician in the absence of disease progression or unacceptable toxicity.
GROUP II (LOCAL THERAPY): Participants receive fluorouracil and capecitabine and undergo radiation therapy (RT) per instructions of the treating physician in the absence of disease progression or unacceptable toxicity. Participants may also undergo surgery to some or all of the remaining sites of disease as is clinically prudent and indicated by treating physician.
After completion of study treatment, participants are followed up at 4-8 weeks, 2-3 months, every 3-6 months for up to 3 years, and then every 6-12 months thereafter.
研究の種類
入学 (推定)
段階
- フェーズ2
連絡先と場所
研究連絡先
- 名前:Quynh Nhu Nguyen, MD
- 電話番号:713-563-2300
- メール:qnnguyen@mdanderson.org
研究場所
-
-
Texas
-
Houston、Texas、アメリカ、77030
- 募集
- M D Anderson Cancer Center
-
コンタクト:
- Quynh-Nhu Nguyen
- 電話番号:713-563-2300
-
主任研究者:
- Quynh-Nhu Nguyen
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
-
The patient has a pathologic diagnosis of tumor biopsy or FNA of esophageal or gastric cancer of adenocarcinoma histology
-
The patient is staged with EGD and PET/CT scan.
-
The patient has three or less observable metastatic lesions. Patients may have three or less radiographically visible metastatic lesions at diagnosis or if have regressed to three or less metastatic lesions after induction chemotherapy at time of randomization. The patient must have pathologic confirmation and or radiologically visible disease. For esophageal tumors, the maximal dimension of the primary tumor may not provide reproducible measurements for RECIST and may not be visible on CT or PET/CT at diagnosis or after induction chemotherapy. Accordingly, patients are eligible regardless of the imaging measurements of the primary tumor. Additionally, in patients with non-measurable metastases, patients are eligible if there is pathology confirming metastases from a distant site. However, biopsy of a metastatic site is not required if there are visible metastases on imaging (such as ultrasound, diagnostic CT , EUS, PET/CT).
- The patient has three or less observable metastatic lesions by diagnostic scans (CT scan, PET/CT, eEndoscopic ultrasound, MRI, or bone scan). Metastatic lesions include distant M1 lymph node group; which will be counted as one site (M1 metastatic lymph nodes to include cervical, mediastinal, gastric, retroperitoneal lymph nodes will be counted as one lesion).
- Osseous metastases or visceral metastases will each count as one metastatic site.
- Each CNS metastases will count as one metastatic site.
- Satellite lesions in the primary esophageal malignancy such as skipped esophageal primaries are not considered metastatic sites. Symptomatic metastatic sites can be treated locally prior to randomization or by palliative radiation.
- Symptomatic metastatic sites may be treated with radiation or surgery prior to enrollment.
-
Patient ECOG of 0-2, with life expectancy of at least 6 months
-
Patients age >18 yrs old but <80 yrs old and signed informed consent
-
Women of child-bearing age must have pregnancy test at time of enrollment, agree to use of adequate contraception (birth control hormone or barrier method) for the duration of the study and for six months after discontinuation of systemic agents.
Exclusion Criteria:
-
Patients with prior chemotherapy or radiation therapy for their diagnosis of esophageal or gastric cancer. Patients with prior radiation therapy to same site for another diagnosis of cancer. Note: Patients may receive palliative radiation to their symptomatic sites of metastases but not definitive local therapy to esophageal or gastric primary prior to randomization. All patients may be enrolled on protocol then start systemic therapy; if they do not have evidence of disease progression at re-staging following initial therapy, they may be randomized.
-
Patients with fistula documented radiographically or by EDG/EUS, EBUS.
-
Patients with life expectancy less than 6 months, ECOG >3
-
Female patients who are pregnant confirmed by bHCG lab test.
-
Patient has history of uncontrolled angina, congestive heart failure or recent MI within 6 months.
-
Nursing females
-
Patients in poor nutritional state
-
Patients with:
- Severely depressed bone marrow function
- Potentially serious infections
- Known hypersensitivity to 5-fluorouracil
- Known or suspected to have a dihydropyrimidine dehydrogenase deficiency (as these patients are at a greater risk of experiencing symptoms of toxicity)
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Group I (maintenance chemotherapy)
Participants receive fluorouracil and capecitabine per instructions of the treating physician in the absence of disease progression or unacceptable toxicity. |
Patients will receive 5-fluorouracil (5-FU) and capecitabine as maintenance chemotherapy.
他の名前:
Receive induction chemotherapy
他の名前:
Patients will receive 5-fluorouracil (5-FU) and capecitabine as maintenance chemotherapy.
他の名前:
|
|
実験的:Group II (local therapy)
Participants receive fluorouracil and capecitabine and undergo RT per instructions of the treating physician in the absence of disease progression or unacceptable toxicity. Participants may also undergo surgery to some or all of the remaining sites of disease as is clinically prudent and indicated by treating physician. |
Undergo surgery Undergo RT
他の名前:
Patients will receive 5-fluorouracil (5-FU) and capecitabine as maintenance chemotherapy.
他の名前:
Receive induction chemotherapy
他の名前:
Patients will receive 5-fluorouracil (5-FU) and capecitabine as maintenance chemotherapy.
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Overall survival (OS)
時間枠:Up to 6 years
|
OS distributions in the two arms will be estimated by the method of Kaplan and Meier. Bayesian piecewise exponential regression will be used to assess the relationships between each of OS and PFS, and patients' covariates and treatment arm. |
Up to 6 years
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Local progression-free survival (PFS)
時間枠:Up to 6 years
|
PFS distributions in the two arms will be estimated by the method of Kaplan and Meier. Bayesian piecewise exponential regression will be used to assess the relationships between each of OS and PFS, and patients' covariates and treatment arm. |
Up to 6 years
|
|
Distant PFS
時間枠:Up to 6 years
|
PFS distributions in the two arms will be estimated by the method of Kaplan and Meier. Bayesian piecewise exponential regression will be used to assess the relationships between each of OS and PFS, and patients' covariates and treatment arm. |
Up to 6 years
|
|
Incidence of adverse events
時間枠:Up to 6 years
|
Graded according to Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. |
Up to 6 years
|
|
Time to local or regional disease recurrence
時間枠:Up to 6 years
|
To be analyzed by Bayesian piecewise regression to assess their relationships with treatment arm and prognostic covariates. |
Up to 6 years
|
その他の成果指標
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Time to local disease recurrence
時間枠:Up to 6 years
|
To be analyzed by Bayesian piecewise regression to assess their relationships with treatment arm and prognostic covariates. |
Up to 6 years
|
|
Time to disease progression
時間枠:Up to 6 years
|
To be analyzed by Bayesian piecewise regression to assess their relationships with treatment arm and prognostic covariates. |
Up to 6 years
|
協力者と研究者
捜査官
- 主任研究者:Quynh-Nhu Nguyen、M.D. Anderson Cancer Center
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- 2016-0972
- 2016-0972 (その他の識別子:M D Anderson Cancer Center)
- NCI-2018-01202 (レジストリ識別子:CTRP (Clinical Trial Reporting Program))
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。